X4 Pharmaceuticals (XFOR) Capital Expenditures (QoQ) (2017 - 2024)
X4 Pharmaceuticals (XFOR) Capital Expenditures (QoQ) (2017 - 2024) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,192.35 Bn | 67,192.06 Bn | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - |
| 4 | BeOne Medicines | 471.52 Bn | 466.73 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.73 Bn | 114.48 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.88 Bn | 61.13 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.11 Bn | 63.11 Bn | - |
| 8 | Argenx Se | 55.88 Bn | 50.70 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.48 Bn | 37.48 Bn | - |
| 10 | X4 Pharmaceuticals | 167.50 Mn | -49.55 Mn | 2.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -55.43% |
| Sep 30, 2024 | -31.34% |
| Jun 30, 2024 | 127.12% |
| Jun 30, 2023 | -200.00% |
| Mar 31, 2023 | -73.53% |
| Dec 31, 2022 | 277.78% |
| Sep 30, 2022 | -76.32% |
| Jun 30, 2022 | 72.73% |
| Mar 31, 2022 | 69.23% |
| Dec 31, 2021 | -97.84% |
| Sep 30, 2021 | 221.37% |
| Jun 30, 2021 | -200.00% |
| Mar 31, 2021 | 171.88% |
| Dec 31, 2020 | -146.37% |
| Sep 30, 2020 | 16,433.33% |
| Jun 30, 2020 | -98.38% |
| Mar 31, 2020 | 568.67% |
| Dec 31, 2019 | 2.47% |
| Sep 30, 2019 | 710.00% |
| Dec 31, 2017 | 1,672.22% |